GSMA Announces New Speakers for Mobile 360 Series – MENA
The GSMA today announced a number of additional high-profile speakers for its Mobile 360 Series – MENA (Middle East and North Africa) conference taking place on the 26-27 November 2018 in Dubai. The mobile industry-focused event, which is now in its sixth year, will cover the key industry issues facing the region, with a particular emphasis on transformative technologies including artificial intelligence (AI), blockchain and 5G.
“Mobile is having a transformative impact across this diverse region with mobile operators in the GCC states laying the foundations for leadership in 5G and planning ahead to commercial launches, while the region’s emerging markets are seeing rising smartphone adoption,” said John Giusti, Chief Regulatory Officer, GSMA. “We have a incredible line-up of expert speakers this year, ready to outline the key issues and challenges facing the region – we’re looking forward to a thought-provoking and exciting showcase.”
New speakers added to the agenda include:
- Hakam Kanafani, Chairman of the Board, Arab Advisors Group
- Ola Doudin, CEO, BitOasis
- Sandra De Zoysa, Chief Customer Officer, Dialog Sri Lanka
- Saleem Alblooshi, Chief Infrastructure Officer, Du
- Chafic Traboulsi, Regional VP, Head of Networks Middle East, Ericsson
- Khalifa Hassan Al-Forah Al-Shamsi, Group Chief Corporate Strategy and Governance Officer, Etisalat
- Dr. Mohamed Madkour, VP Global Wireless Networks Marketing and Solutions, Huawei
- Ramit Harisinghani, Vice President/Head of MEA, HTC
- Ouassim El Arroussi – Marketing B2B Director, INWI
- Bashar Arafeh, Managing Director, MEA, Irisguard
- Elcin Yanik, EVP Market Development, Mastercard
- Dr. Atef Helmy, Senior Advisor, Board of Directors, Orange Middle East and Africa
- Madhu Dua, Vice President, Reliance Jio
- Dr Homoud Mohammed Alkussayer, Governance and Regulatory Affairs Sector VP, STC
They join previously announced speakers including:
- Hatem Dowidar, CEO International, Etisalat
- Imen Benzine, CMO, Algerie Telecom
- Dr Ling Wu, Chairman, Carrier Blockchain Study Group (CBSG) Consortium
- Osman Sultan, CEO, Du
- Rafiah Ibrahim, President Middle East and Africa, Ericsson
- Mohie Elrafey, CMO, GE Healthcare, Eastern Growth Markets
- Jawad Abbassi, Head of MENA, GSMA
- John Giusti, Chief Regulatory Officer, GSMA
- Anthony Butler, Leader and Chief Technology Officer, IBM Blockchain Services, Middle East and Africa
- Jaime Galviz, COO and CMO, Microsoft MEA
- Thierry Millet, CEO, Orange Tunisia
- Navin Gupta, Managing Director, South Asia and MENA, Ripple
- Daichi Nozaki, VP Global Business, SoftBank
- Nasser bin Suleiman Al-Nasser, CEO, STC
- Ahmed El Beheiry, CEO, Telecom Egypt
- Aysem Ertopuz, EVP Digital Services and Solutions, Turkcell
- Scott Gegenheimer, CEO Operations, Zain Group
Being held at the new location of the Westin Mina Seyahi Hotel in Dubai, the two-day Mobile 360 – MENA will bring together senior-level delegates from across the region to discuss the key developments in the mobile industry and their impact on businesss and citizens across the region. Topics will include cybersecurity risk, digital identity and the Internet of Things, as well as an in-depth focus on the policy and regulatory approaches needed to drive further innovation in the 5G era.
New Sponsors
A number of new industry sponsors have
recently signed up to support the event, including Telecom Egypt, who
have joined as Mobile Partner, alongside Mastercard as Industry Sponsor,
Irisgard as Showcase Sponsors and Novation City as Supporting Sponsor.
They join previously announced sponsors including Etisalat (Host
Sponsor), Huawei (Headline Sponsor), and Ericsson, Facebook, Intelsat
and Matrixx Software (Supporting Sponsors).
For further information on Mobile 360 – MENA, including sponsorship opportunities, please visit www.mobile360series.com/mena/. Follow developments and updates on Mobile 360 – MENA (#M360MENA) on Twitter @GSMAEVENTS, on Facebook www.facebook.com/Mobile360Series and LinkedIn on www.linkedin.com/company/gsma-mobile-360-series. Download the event app for further information: www.mobile360series.com/app/.
-ENDS-
About the GSMA
The GSMA represents the interests of mobile
operators worldwide, uniting more than 750 operators with over 350
companies in the broader mobile ecosystem, including handset and device
makers, software companies, equipment providers and internet companies,
as well as organisations in adjacent industry sectors. The GSMA also
produces the industry-leading MWC events held annually in Barcelona, Los
Angeles and Shanghai, as well as the Mobile 360 Series of regional
conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181119005230/en/
Contact information
Media Contacts:
Asad Abbasi
+971 52 861 4230
AAbbasi@webershandwick.com
GSMA Press Office
mobile360pressoffice@gsma.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new